Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | REPS1 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | HMGN3 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | ATAT1 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | DRAP1 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
mRNA | USP49 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | IP6K2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | PIKFYVE | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
mRNA | NUP58 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | C4orf46 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
mRNA | UBQLN2 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |